Trevi Therapeutics, Inc. received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine. The patent numbers are 8,771,732 and 8,765,175.

The Company believes that both of these patents will be Orange Book-listable. These two patents complement two additional issued formulation patents, as well as an issued patent protecting the method of use of Nalbuphine ER in the “Methods for Treatment of Pruritus,” which expires in December 2032. Trevi continues to prosecute additional claims to further enhance its existing patent estate protecting Nalbuphine ER in itch.

Jennifer Good, Trevi's President and Chief Executive Officer, said, “We are pleased with the issued patent estate to date and will continue to pursue opportunities to protect Nalbuphine ER. Nalbuphine's novel mechanism of action aligns well with multiple itch conditions, and we have initiated a pivotal trial in uremic pruritus and will be initiating a pivotal trial in prurigo nodularis later this year.”